The rising prevalence of pediatric type 1 diabetes (T1D) and the limitations of traditional management necessitate a critical review of innovative therapies that can improve both glycemic outcomes and quality of life. This article synthesizes the current evidence and practical considerations surrounding 2 pivotal advancements: advanced hybrid closed-loop systems and adjunctive pharmacological therapies. The review first details the evolution from open-loop to sophisticated advanced hybrid closed-loop systems, explicating their core technologies, functionality, and demonstrated clinical efficacy in pediatric populations. It then analyzes the multifaceted impact of advanced hybrid closed-loop systems on key glycemic metrics—such as time in range and hypoglycemia risk—and patient-reported quality of life. Subsequently, the article addresses the significant implementation challenges, including technical, psychological, and cost-related barriers. Furthermore, it examines the role and benefits of adjunctive pharmacological therapies in modern pediatric care. Finally, it explores the promising integration of these adjunctive treatments with automated insulin delivery to create synergistic, personalized management strategies. By consolidating this evidence, the review aims to inform clinical practice and highlight areas where current paradigms are successfully evolving. Future progress hinges on overcoming accessibility inequities and advancing research toward fully automated, multi-hormone systems and broadly accessible adjunctive treatment protocols.

View PDF